Welcome to our dedicated page for Enanta Pharmaceuticals news (Ticker: ENTA), a resource for investors and traders seeking the latest updates and insights on Enanta Pharmaceuticals stock.
Enanta Pharmaceuticals, Inc. develops small-molecule drugs for viral infections and immunological diseases through a chemistry-driven drug discovery approach. News about the company commonly covers its respiratory syncytial virus programs, including zelicapavir, an oral N-protein inhibitor, and EDP-323, an L-protein inhibitor, as well as clinical data presentations at medical and scientific conferences.
Enanta updates also focus on immunology programs targeting drivers of type 2 immune responses, including KIT, STAT6 and MRGPRX2 inhibition. Company releases frequently address candidates such as EDP-978 and EPS-3903, research and development progress, quarterly financial results, management conference participation and royalty revenue tied to its collaboration history.
Enanta Pharmaceuticals (NASDAQ:ENTA) reported $18.7 million in royalty revenue for Q2 2022, a decrease from $20.1 million in Q2 2021. The net loss widened to $33.6 million, or $1.63 per share, compared to a loss of $22.0 million, or $1.09 per share, year-on-year. The company expects topline data from the Phase 2b RSVP study for EDP-938 and preliminary results from the Phase 1 EDP-235 study this quarter, with Fast Track designations granted for both. Enanta’s cash reserves stand at $322.5 million, expected to last for at least two years, supporting ongoing development programs.
Enanta Pharmaceuticals plans to report its financial results for the fiscal second quarter ended March 31, 2022, on May 9, 2022. A conference call will follow at 4:30 p.m. ET to discuss results and updates on the company's research pipeline, which focuses on small molecule drugs for viral infections and liver diseases, including targets like RSV, COVID-19, and HBV. Enanta's R&D is funded by royalties from HCV products developed in collaboration with AbbVie, notably Glecaprevir, part of its leading treatment for chronic HCV infections.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced that the FDA has granted Fast Track designation for EDP-235, an oral COVID-19 treatment targeting the coronavirus 3CL protease. This designation allows for expedited development due to the ongoing need for effective treatments against SARS-CoV-2. EDP-235 is currently undergoing a Phase 1 study assessing its safety and dosage. Preclinical data indicates it effectively blocks SARS-CoV-2 replication, positioning it as a leading candidate among direct-acting antivirals. Enanta expects to share Phase 1 data next quarter.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that its CEO, Jay R. Luly, Ph.D., will present at the Oppenheimer 32nd Annual Healthcare Conference on March 15, 2022, at 4:40 p.m. ET. Investors can access a live webcast on Enanta's website under the "Events and Presentations" section, with a replay available for 30 days post-event. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with clinical candidates targeting RSV, SARS-CoV-2, and HBV. The company is funded by royalties from its HCV collaboration with AbbVie.
Enanta Pharmaceuticals (NASDAQ:ENTA) announced the publication of positive results from its Phase 2a human challenge study of EDP-938 for treating respiratory syncytial virus (RSV) in The New England Journal of Medicine. The study demonstrated significant reductions in viral load and symptom scores compared to placebo, with p-values 0.001. EDP-938 exhibited good pharmacokinetics and a favorable safety profile, being well tolerated without serious adverse events. The company is advancing through further clinical studies, including Phase 2 studies in pediatric patients and other groups.
Enanta Pharmaceuticals has initiated a Phase 1 clinical trial for EDP-235, a novel coronavirus 3CL protease inhibitor aimed at treating COVID-19. This milestone is crucial as SARS-CoV-2 continues to pose a global health threat, with EDP-235 designed for once-daily oral administration. The trial will assess safety, tolerability, and pharmacokinetics in healthy volunteers. Promising preclinical data indicate EDP-235's potent antiviral activity, with an exceptional EC90 of 33 nanomolar, positioning it as a potential best-in-class treatment. Initial results are expected in Q2 2022, with further developments planned for later in the year.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced that CEO Jay R. Luly, Ph.D., will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022, at 3:00 p.m. ET. The event will be accessible via a live webcast on Enanta's website, with a replay available for 90 days. Enanta is focused on developing small molecule drugs targeting viral infections and liver diseases, with key research in areas such as RSV, COVID-19, and HBV, supported by royalties from HCV products developed with AbbVie.
Enanta Pharmaceuticals reported fiscal Q1 2021 revenues of $27.6 million, primarily from royalty revenue linked to AbbVie’s MAVYRET. R&D expenses surged to $48.5 million, reflecting increased clinical study support. The net loss widened to $30.1 million, or $1.48 per share. The company has completed enrollment in its Phase 2b study of EDP-938 for RSV, with topline data expected in Q2 2022. Additionally, they are set to begin a Phase 1 trial for EDP-235, an oral treatment for COVID-19, this month.
Enanta Pharmaceuticals (NASDAQ: ENTA) will report its fiscal Q1 results for the period ending December 31, 2021, on February 8, 2022, post-market. The company will hold a conference call at 4:30 p.m. ET to discuss these results and its R&D pipeline. Enanta focuses on developing small molecule drugs targeting viral infections and liver diseases. Its R&D is supported by royalties from its collaboration with AbbVie on hepatitis C products, notably Glecaprevir, which is marketed as MAVYRET® and MAVIRET®.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced key developments for 2022 during the J.P. Morgan Healthcare Conference on January 11. The company plans to initiate a Phase 1 study of EDP-235, a COVID-19 treatment, in February 2022. Additionally, enrollment is complete for the Phase 2 RSVP study of EDP-938 for RSV, with data expected in Q2 2022. Enanta also introduced EDP-323, a new RSV candidate, aiming for a Phase 1 study in H2 2022. The company remains focused on advancing its virology pipeline and addressing urgent healthcare needs amid ongoing challenges from emerging COVID-19 variants.